A new strategy to stabilize oxytocin in aqueous solutions: II. Suppression of cysteine-mediated intermolecular reactions by a combination of divalent metal ions and citrate

Molecular Pharmaceutics

Volumn 9, Issue 3, 2012, Pages 554-562

  Avanti, Christina ^a   Permentier, Hjalmar P ^a   Dam, Annie Van ^a   Poole, Robert ^b   Jiskoot, Wim ^b   Frijlink, Henderik W ^a   Hinrichs, Wouter L J ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

Author keywords

aqueous solution; citrate buffer; degradation; divalent metal ions; oxytocin

Indexed keywords

CALCIUM ION; CITRIC ACID; MAGNESIUM ION; OXYTOCIN; OXYTOCIN DERIVATIVE; ZINC ION;

AQUEOUS SOLUTION; ARTICLE; COMPLEX FORMATION; DRUG DEGRADATION; DRUG DETERMINATION; DRUG FORMULATION; DRUG STABILITY; HEAT STRESS; LIQUID CHROMATOGRAPHY; MOLECULAR INTERACTION; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

CATIONS, DIVALENT; CITRIC ACID; CYSTEINE; DRUG STABILITY; METALS; MOLECULAR STRUCTURE; OXYTOCIN;

EID: 84858021902     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp200622z     Document Type: Article

References (23)

1. Dale, H. H. The Action of Extracts of the Pituitary Body Biochem. J. 1909, 4, 427-447
2. Karbiwnyk, C. M.; Faul, K. C.; Turnipseed, S. B.; Andersen, W. C.; Miller, K. E. Determination of oxytocin in a dilute IV solution by LC-MS(n) J. Pharm. Biomed. Anal. 2008, 48, 672-7
3. Owen, J.; Hauth, J. C. Oxytocin for the induction or augmentation of labor Clin. Obstet. Gynecol. 1992, 35, 464-75
4. Chaibva, F. A.; Walker, R. B. Development and validation of a stability-indicating analytical method for the quantitation of oxytocin in pharmaceutical dosage forms J. Pharm. Biomed. Anal. 2007, 43, 179-85 (Pubitemid 44856219)
5. Gard, J. W.; Alexander, J. M.; Bawdon, R. E.; Albrecht, J. T. Oxytocin preparation stability in several common obstetric intravenous solutions Am. J. Obstet. Gynecol. 2002, 186, 496-8 (Pubitemid 34234163)
6. Turner, R. A.; Pierce, J. G.; du Vigneaud, V. The purification and the amino acid content of vasopressin preparations J. Biol. Chem. 1951, 191, 21-28
7. Davoll, H.; Turner, R. A.; Pierce, J. G.; du Vigneaud, V. An investigation of the free amino groups on oxytocin and desulfurized oxytocin preparations J. Biol. Chem. 1951, 193, 363-370
8. Winkler, M.; Rath, W. A risk-benefit assessment of oxytocics in obstetric practice Drug. Saf. 1999, 20, 323-45 (Pubitemid 29196910)
9. du Vigneaud, V; Ressler, C; Trippett, S. The sequence of amino acids in oxytocin, with a proposal for the structure of oxytocin J. Biol. Chem. 1953, 205, 949-957
10. 2+: I. CD and fluorescence spectral characterization and comparison with vasopressin Biopolymers 1996, 40, 433-43
11. Gimpl, G.; Fahrenholz, F. The oxytocin receptor system: structure, function, and regulation Physiol. Rev. 2001, 81, 629-83 (Pubitemid 32267075)
12. Hogerzeil, H. V.; Walker, G. J. A.; De Goeje, M. J. Stability of injectable oxytocics in tropical climates; World Health Organization: Geneva, 1993; WHO/DAP/93.6.
13. Hawe, A.; Poole, R.; Romeijn, S.; Kasper, P.; van der Heijden, R.; Jiskoot, W. Towards heat-stable oxytocin formulations: analysis of degradation kinetics and identification of degradation products Pharm. Res. 2009, 26, 1679-88
14. Poole, R. A.; Kasper, P. T.; Jiskoot, W. Formation of amide- and imide-linked degradation products between the peptide drug oxytocin and citrate in citrate-buffered formulations J. Pharm. Sci. 2011, 100, 3018-3022
15. Avanti, C.; Amorij, J. P.; Setyaningsih, D.; Hawe, A.; Jiskoot, W.; Visser, J.; Kedrov, A.; Driessen, A. J.; Hinrichs, W. L.; Frijlink, H. W. A new strategy to stabilize oxytocin in aqueous solutions: I. The effects of divalent metal ions and citrate buffer AAPS J. 2011, 13, 284-290
16. The United States Pharmacopeial Convention, Rockville, MD, 2005; USP-29 NF-24.
17. Shaw, G. S. Synthetic calcium-binding peptides Methods Mol. Biol. 2002, 173, 175-82
18. Huck, C. W.; Pezzei, V.; Schmitz, T.; Bonn, G. K.; Bernkop-Schnurch, A. Oral peptide delivery: are there remarkable effects on drugs through sulfhydryl conjugation? J. Drug Targeting 2006, 14, 117-25 (Pubitemid 43878820)
19. Manning, M. C.; Chou, D. K.; Murphy, B. M.; Payne, R. W.; Katayama, D. S. Stability of protein pharmaceuticals: an update Pharm. Res. 2010, 27, 544-75
20. Bulaj, G. Formation of disulfide bonds in proteins and peptides Biotechnol. Adv. 2005, 23, 87-92 (Pubitemid 41512095)
21. Joint FAO/WHO Expert Committee on Food Additives. Citric acid and its calcium, potassium and sodium salts; 1974; Vol. 539.
22. Wyttenbach, T.; Liu, D.; Bowers, M. T. Interactions of the hormone oxytocin with divalent metal ions J. Am. Chem. Soc. 2008, 130, 5993-6000 (Pubitemid 351620846)
23. Pearlmutter, A. F.; Soloff, M. S. Characterization of the metal ion requirement for oxytocin-receptor interaction in rat mammary gland membranes J. Biol. Chem. 1979, 254, 3899-906 (Pubitemid 9178802)